A new first-of-its-kind screening trial is thought to change the lives of men across Lincolnshire and Newark
Prostate Cancer is the most common cancer amongst men, and around 12,000 die of it each year
Last updated 21st Nov 2023
Men across Lincolnshire and Newark could be better protected from the most common cancer amongst them, with a new first-of-its-kind screening trial,
12,000 die of Prostate Cancer every year, and until now, they've have been left to wait until the cancer grew large enough to cause symptoms and become difficult to treat.
Under a new trial though - screening methods like an MRI scan will be used to try and detect the cancer.
Transform
Thousands of men’s lives could be saved, and their loved ones spared the tragedy of losing someone to cancer, as a major new prostate cancer screening trial is set to get under way in the UK backed by £42 million from the government and Prostate Cancer UK.
The first-of-its-kind trial – called TRANSFORM – will use innovative screening methods like an MRI scan to detect prostate cancer, and it will see hundreds of thousands of men across the country participating.
Prostate cancer is the most common cancer in men in the UK and has no screening programme. It usually has no symptoms until it has grown large and may be more difficult to treat and, sadly, 12,000 men die of it every single year.
A way of effectively screening for prostate cancer could find these men before their cancer spreads and save their lives.
The trial has the potential to see new screening methods give more accurate results than the current blood tests, which can miss some cancers and often suggest prostate cancer when no cancer exists.
Crucially, screening could also spot the disease even when no symptoms are displayed.
Health and Social Care Secretary - and the Louth and Horncastle MP - Victoria Atkins said:
“Cancer survival rates continue to improve in the UK, with the disease being diagnosed at an earlier stage more often. But more must be done.
“Our hope is that this funding will help to save the lives of thousands more men through advanced screening methods that can catch prostate cancer as early as possible.”
Laura Kerby, Chief Executive at Prostate Cancer UK, said:
“12,000 men die of prostate cancer each year and it’s the most common cancer that doesn’t have a national screening programme.
“It’s about time that changed. That’s why we’re launching our biggest and most ambitious trial ever. It will finally give us the answers we need to develop a routine testing system and save thousands of men each year.
“Prostate Cancer UK's unique focus and expertise made us the only organisation that could really deliver this paradigm-shifting trial, and we’re delighted that the Government has backed our vision to revolutionise diagnosis.”
1 in 4 Black men will develop prostate cancer – double the risk of other men. Therefore, to ensure the trial helps reduce their risk of dying from this disease, 1 in 10 men invited to participate will be Black men. Participating men in the screening trial will be aged 50-75, with Black men eligible from the lower age range of 45-75.
Men at higher risk of prostate cancer due to age and ethnicity will be recruited through their GP practice and invited to a screening visit.
More than 52,000 men are diagnosed with prostate cancer every year in the UK on average – that’s 144 men every day. Around 490,000 men are currently living with and after prostate cancer.
Wilf Baker is in remission from the disease - and Chairs the Lincs and Humber Prostate Cancer Support Group
He says his was caught early:
"I went to my doctor and I was sent to the hospital and then I had an MRI scan and they said 'yes, yes it's cancerous'.
"I needed treatment and radiotherapy, but thanks to the NHS, they saved my life.
"When I finally got told I had prostate cancer, I went to see the consultant and he gave me a leaflet about a local support group... I think sometimes, if there's somebody there to talk to... it can be so vital."
To find out more about the support group go to Prostate Cancer Lincs and Humber.
£16 million will be invested by the government for the trial through the National Institute of Health Research and Prostate Cancer UK, who have led the development of the trial, will provide £26m. The trial is due to start in Spring 2024 with recruitment likely to begin in Autumn 2024.
The government has already opened 127 community diagnostic centres to offer quicker, more convenient checks outside of hospitals for conditions such as cancer, with over 5 million additional tests delivered so far.
The Major Conditions Strategy will also consider the prevention, diagnosis, treatment and management of conditions including cancer. The UK is already working with world renowned scientists to deliver new cancer vaccine trials and is growing the size of the specialist workforce.